» Articles » PMID: 38985396

Synthesis of Two Fluorescent Complexes and Their Use As Multifunctional Nanomedicine Carriers for Rhabdomyosarcoma Treatment

Overview
Journal J Fluoresc
Specialties Biophysics
Chemistry
Date 2024 Jul 10
PMID 38985396
Authors
Affiliations
Soon will be listed here.
Abstract

This study focuses on the design and synthesis of two novel coordination polymers (CPs), named 1 and 2, with excellent fluorescent properties. Their structures were characterized by X-ray single-crystal diffraction, revealing that both materials exhibit promising fluorescence performance, indicating their potential as fluorescent detection tools. Additionally, 1 was chosen to be combined with chitosan (CS), resulting in the successful fabrication of a biodegradable and non-toxic efficient drug carrier, termed CS-1@Cisplatin. This carrier possesses a large surface area and good solubility, enabling sustained drug release to target cells. Given that CXC motif chemokine receptor type 4 (CXCR4) is a key marker gene highly expressed in Rhabdomyosarcoma (RMS) cells and tissues, RMS was chosen as the biological model for testing. The results demonstrated that CS-1@Cisplatin effectively inhibited the invasiveness of RMS cells by significantly suppressing CXCR4 expression. Therefore, the system shows great potential for applications in RMS treatment, biometrics, and drug delivery, particularly in its unique advantage of targeting RMS by inhibiting the key marker gene CXCR4.

References
1.
Martin-Giacalone B, Li H, Scheurer M, Casey D, Dugan-Perez S, Marquez-Do D . Germline Genetic Testing and Survival Outcomes Among Children With Rhabdomyosarcoma: A Report From the Children's Oncology Group. JAMA Netw Open. 2024; 7(3):e244170. PMC: 10979319. DOI: 10.1001/jamanetworkopen.2024.4170. View

2.
Rossi S, Poliani P, Missale C, Monti E, Fanzani A . Caveolins in rhabdomyosarcoma. J Cell Mol Med. 2011; 15(12):2553-68. PMC: 4373424. DOI: 10.1111/j.1582-4934.2011.01364.x. View

3.
Shields J, Shields C . Rhabdomyosarcoma: review for the ophthalmologist. Surv Ophthalmol. 2003; 48(1):39-57. DOI: 10.1016/s0039-6257(02)00415-0. View

4.
Agaram N . Evolving classification of rhabdomyosarcoma. Histopathology. 2021; 80(1):98-108. PMC: 9425116. DOI: 10.1111/his.14449. View

5.
Siebert J, Schneider M, Reuter-Schmitt D, Wurtemberger J, Neubuser A, Driever W . Rhabdomyosarcoma xenotransplants in zebrafish embryos. Pediatr Blood Cancer. 2022; 70(1):e30053. DOI: 10.1002/pbc.30053. View